• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.

April 4, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]
Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S.

The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.

Parsippany, New Jersey–based Ascensia is Senseonics’ global commercial partner. Alongside the Eversense E3, Asensia launched the Eversense PASS savings program to increase patient access to the CGM and its benefits, according to a news release. The company designed Eversense PASS to allow users to pay only $99 out of pocket for their first Eversense E3 sensor and smart transmitter and, for each sensor thereafter, users pay no more than $100 per month or $600 for the duration of each sensor wear.

“We are thrilled to offer Eversense E3 to people with diabetes in the U.S. and are proud to do this alongside a favorable Payment Assistance and Savings Program,” Ascensia Diabetes Care President Robert Schumm said in the release. “As the longest-lasting CGM system available at up to 6 months of sensor wear, Eversense E3’s offering is truly differentiated, and we believe it is important to make the system as affordable as possible.”

Senseonics presented data in 2021 that demonstrated strong accuracy with the fully implantable, 180-day sensor. The next-generation platform matched performance levels compared to the 90-day version, but with calibration reduced to essentially once per day. One of the sensor’s tests produced a mean absolute relative difference (MARD) of 8.5%, representing high accuracy.

READ: Senseonics CMO Dr. Francine Kaufman talks about what’s next for the company

Eversense E3 features a third-generation sensor with SBA technology that enhances sensor longevity to make it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.

“The evolution of continuous glucose monitoring has been one of the biggest developments in diabetes care and the Eversense E3 CGM System is another significant step forward for patients,” Ascensia’s Head of the Eversense CGM business unit Elaine Anderson said. “It’s so important to offer choice through a variety of solutions and to listen to what people really need from technology to live life as fully as possible. Eversense E3 exemplifies this approach, offering people with diabetes an exciting new CGM option with outstanding flexibility, convenience and accuracy.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Ascensia Diabetes Care, Senseonics

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS